Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AGEN Agenus Inc
- Stocks
- Healthcare
- NASDAQ: AGEN
Price (delayed)
$3.47
Market cap
$95.14M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$8.57
Enterprise value
$166.73M
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the
Highlights
The EPS is up by 32% year-on-year and by 19% since the previous quarter
AGEN's net income is up by 20% YoY and by 16% QoQ
AGEN's equity has shrunk by 70% YoY and by 4.7% QoQ
The quick ratio has plunged by 57% YoY and by 50% from the previous quarter
Key stats
What are the main financial stats of AGEN
Market
Valuations
Earnings
Shares outstanding
27.42M
Market cap
$95.14M
Enterprise value
$166.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.68
Revenue
$99.52M
Gross profit
$99.01M
Operating income
-$104.86M
Net income
-$190.59M
EBIT
-$89.64M
EBITDA
-$76.47M
Free cash flow
-$146.26M
Per share
Balance sheet
Liquidity
EPS
-$8.57
EPS diluted
-$8.57
Free cash flow per share
-$5.98
Book value per share
-$13.51
Revenue per share
$4.07
TBVPS
$7.06
Total assets
$200.2M
Total liabilities
$522.6M
Debt
$90.08M
Equity
-$341.85M
Working capital
-$185.17M
Debt to equity
-0.26
Current ratio
0.11
Quick ratio
0.09
Net debt/EBITDA
-0.94
Margins
Efficiency
Dividend
EBITDA margin
-76.8%
Gross margin
99.5%
Net margin
-191.5%
Operating margin
-105.4%
Return on assets
-79.7%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-90.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AGEN stock price
How has the Agenus stock price performed over time
Intraday
2.66%
1 week
17.63%
1 month
94.94%
1 year
-67.57%
YTD
26.64%
QTD
130.56%
Financial performance
How have Agenus's revenue and profit performed over time
Revenue
$99.52M
Gross profit
$99.01M
Operating income
-$104.86M
Net income
-$190.59M
Gross margin
99.5%
Net margin
-191.5%
The gross profit has contracted by 38% YoY and by 3.9% from the previous quarter
Agenus's revenue has decreased by 38% YoY and by 3.8% from the previous quarter
Agenus's net margin has decreased by 29% YoY but it has increased by 13% QoQ
AGEN's operating income is up by 24% year-on-year and by 16% since the previous quarter
Price vs fundamentals
How does AGEN's price correlate with its fundamentals
Growth
What is Agenus's growth rate over time
Valuation
What is Agenus stock price valuation
P/E
N/A
P/B
N/A
P/S
0.85
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.68
The EPS is up by 32% year-on-year and by 19% since the previous quarter
AGEN's equity has shrunk by 70% YoY and by 4.7% QoQ
The stock's price to sales (P/S) is 82% less than its 5-year quarterly average of 4.6 and 15% less than its last 4 quarters average of 1.0
Agenus's revenue has decreased by 38% YoY and by 3.8% from the previous quarter
Efficiency
How efficient is Agenus business performance
The return on sales is up by 15% since the previous quarter but it has declined by 13% year-on-year
Agenus's return on assets has increased by 11% QoQ but it has decreased by 7% YoY
Dividends
What is AGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AGEN.
Financial health
How did Agenus financials performed over time
AGEN's total assets is 62% lower than its total liabilities
The quick ratio has plunged by 57% YoY and by 50% from the previous quarter
Agenus's current ratio has shrunk by 54% YoY and by 48% QoQ
Agenus's debt is 126% higher than its equity
AGEN's equity has shrunk by 70% YoY and by 4.7% QoQ
The debt to equity is up by 33% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.